These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Down-regulation of mu-opioid receptor by full but not partial agonists is independent of G protein coupling. Yabaluri N; Medzihradsky F Mol Pharmacol; 1997 Nov; 52(5):896-902. PubMed ID: 9351981 [TBL] [Abstract][Full Text] [Related]
6. The mu opioid irreversible antagonist beta-funaltrexamine differentiates the discriminative stimulus effects of opioids with high and low efficacy at the mu opioid receptor. Morgan D; Picker MJ Psychopharmacology (Berl); 1998 Nov; 140(1):20-8. PubMed ID: 9862398 [TBL] [Abstract][Full Text] [Related]
7. Neutral antagonist activity of naltrexone and 6beta-naltrexol in naïve and opioid-dependent C6 cells expressing a mu-opioid receptor. Divin MF; Bradbury FA; Carroll FI; Traynor JR Br J Pharmacol; 2009 Apr; 156(7):1044-53. PubMed ID: 19220294 [TBL] [Abstract][Full Text] [Related]
8. Differential binding properties of oripavines at cloned mu- and delta-opioid receptors. Lee KO; Akil H; Woods JH; Traynor JR Eur J Pharmacol; 1999 Aug; 378(3):323-30. PubMed ID: 10493109 [TBL] [Abstract][Full Text] [Related]
9. Use of beta-funaltrexamine to determine mu opioid receptor involvement in the analgesic activity of various opioid ligands. Zimmerman DM; Leander JD; Reel JK; Hynes MD J Pharmacol Exp Ther; 1987 May; 241(2):374-8. PubMed ID: 3033213 [TBL] [Abstract][Full Text] [Related]
10. Differential opioid agonist regulation of the mouse mu opioid receptor. Blake AD; Bot G; Freeman JC; Reisine T J Biol Chem; 1997 Jan; 272(2):782-90. PubMed ID: 8995364 [TBL] [Abstract][Full Text] [Related]
11. Paradoxical relationship between RAVE (relative activity versus endocytosis) values of several opioid receptor agonists and their liability to cause dependence. Wang YH; Sun JF; Tao YM; Xu XJ; Chi ZQ; Liu JG Acta Pharmacol Sin; 2010 Apr; 31(4):393-8. PubMed ID: 20228826 [TBL] [Abstract][Full Text] [Related]
12. Chronic exposure to mu-opioid agonists produces constitutive activation of mu-opioid receptors in direct proportion to the efficacy of the agonist used for pretreatment. Liu JG; Prather PL Mol Pharmacol; 2001 Jul; 60(1):53-62. PubMed ID: 11408600 [TBL] [Abstract][Full Text] [Related]
13. Characterization of opioid agonist efficacy in a C6 glioma cell line expressing the mu opioid receptor. Emmerson PJ; Clark MJ; Mansour A; Akil H; Woods JH; Medzihradsky F J Pharmacol Exp Ther; 1996 Sep; 278(3):1121-7. PubMed ID: 8819494 [TBL] [Abstract][Full Text] [Related]
14. Opioid peptide receptor studies. 7. The methylfentanyl congener RTI-4614-4 and its four enantiomers bind to different domains of the rat mu opioid receptor. Lu YF; Xu H; Liu-Chen LY; Chen C; Partilla JS; Brine GA; Carroll FI; Rice KC; Lai J; Porreca F; Sadee W; Rothman RB Synapse; 1998 Feb; 28(2):117-24. PubMed ID: 9450512 [TBL] [Abstract][Full Text] [Related]
15. Discriminative stimulus effects of the mixed-opioid agonist/antagonist dezocine: cross-substitution by mu and delta opioid agonists. Picker MJ J Pharmacol Exp Ther; 1997 Dec; 283(3):1009-17. PubMed ID: 9399970 [TBL] [Abstract][Full Text] [Related]
16. Effect of the A118G polymorphism on binding affinity, potency and agonist-mediated endocytosis, desensitization, and resensitization of the human mu-opioid receptor. Beyer A; Koch T; Schröder H; Schulz S; Höllt V J Neurochem; 2004 May; 89(3):553-60. PubMed ID: 15086512 [TBL] [Abstract][Full Text] [Related]
17. Agonist-induced signaling and trafficking of the mu-opioid receptor: role of serine and threonine residues in the third cytoplasmic loop and C-terminal domain. Capeyrou R; Riond J; Corbani M; Lepage JF; Bertin B; Emorine LJ FEBS Lett; 1997 Sep; 415(2):200-5. PubMed ID: 9350996 [TBL] [Abstract][Full Text] [Related]
18. Differential effects of opioid agonists on G protein expression in CHO cells expressing cloned human opioid receptors. Xu H; Wang X; Partilla JS; Bishop-Mathis K; Benaderet TS; Dersch CM; Simpson DS; Prisinzano TE; Rothman RB Brain Res Bull; 2008 Sep; 77(1):49-54. PubMed ID: 18639745 [TBL] [Abstract][Full Text] [Related]
19. A comparison of noninternalizing (herkinorin) and internalizing (DAMGO) mu-opioid agonists on cellular markers related to opioid tolerance and dependence. Xu H; Partilla JS; Wang X; Rutherford JM; Tidgewell K; Prisinzano TE; Bohn LM; Rothman RB Synapse; 2007 Mar; 61(3):166-75. PubMed ID: 17152090 [TBL] [Abstract][Full Text] [Related]
20. Opioid agonist efficacy predicts the magnitude of tolerance and the regulation of mu-opioid receptors and dynamin-2. Pawar M; Kumar P; Sunkaraneni S; Sirohi S; Walker EA; Yoburn BC Eur J Pharmacol; 2007 Jun; 563(1-3):92-101. PubMed ID: 17349996 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]